Vor Biopharma (VOR) Cut Quarterly Losses, Is The Stock Still Below Fair Value?
Why Vor Biopharma’s Latest Quarterly Results Matter
Vor Biopharma (VOR) reported third quarter figures on October 30, 2026, with net losses and loss per share sharply lower than a year earlier, alongside a new US$150 million at-the-market equity program.
Vor Biopharma’s recent quarterly update and the US$150 million at the market offering landed as the share price logged a 70.79% year to date share price return, even though the 90 day share price return declined 15.73% and the 3 year total shareholder return fell 44.47%. This pattern suggests shorter term momentum has cooled after a strong rebound earlier in 2026, while longer term holders have still experienced significant losses.
See how Vor Biopharma compares with other potential rebound stories by reviewing a hand picked set of 19 high quality undiscovered gems in similar market situations.
Vor Biopharma’s losses have narrowed and the share price has rebounded this year, yet the long term track record is still painful. So do the current numbers justify today’s US$1.22b valuation or not?
Most Popular Narrative: 49% Undervalued
Vor Biopharma last closed at $19.88 while the analyst consensus Narrative on Simply Wall St points to a fair value of $39 per share. This frames the current setup as materially discounted based on those assumptions and long term trial milestones.
Completion of enrollment in the global Phase 3 UPSTREAM trial for generalized myasthenia gravis, with topline data expected in the first half of 2027, positions Vor Biopharma for a potential future launch that could influence revenue growth and operating leverage if key endpoints are met and eventually support commercialization outside China.
See why 1 investors see Vor Biopharma as 49% undervalued.
Result: Fair Value of $39 (UNDERVALUED)
Still, this bullish Vor Biopharma story unravels quickly if Phase 3 telitacicept data disappoint outside China or if competing autoimmune drugs win physician preference.
Find out about the key risks to this Vor Biopharma narrative.
Next Steps
Mixed signals around Vor Biopharma can feel uncomfortable. Move quickly, review the underlying data, and decide where you stand after weighing 3 key rewards and 4 important warning signs
Looking for more investment ideas beyond Vor Biopharma?
Do not stop with Vor Biopharma when a wider set of opportunities could fit your goals. Use targeted screeners to spot ideas before most investors even notice.
- Hunt for mispriced quality by scanning a focused group of 40 high quality undervalued stocks that pair fundamental strength with potentially appealing entry points.
- Prioritize resilience and sleep better at night by zeroing in on a 31 resilient stocks with low risk scores built around businesses with sturdier risk profiles.
- Aim for balance sheet strength and fewer unpleasant surprises by filtering candidates through a list of solid balance sheet and fundamentals (25 results) that highlights financially robust companies.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com